In vitro Comparative Dissolution Studies of Different Propranolol Generic Tablets Available in Bangladesh
Abstract
The present study focused to assess in vitro dissolution profiles of four different products of propranolol 10 mg Tablets (Randomly coded as PRP1-PRP4) available in Bangladesh comparing with the reference brand (coded as REF). Propranolol is a competitive non selective beta-adrenergic receptor antagonist used to amend or restore normal heart rhythm in cardiovascular diseases. An in vitro dissolution study was carried out using the United States Pharmacopoeia (USP) paddle method at 75 rpm with 500 mL of 0.1N HCl dissolution media at 37.0± 0.5 0C. All the tested locally manufactured propranolol products; PRP1, PRP2, PRP3, PRP4 showed compatible dissolution (87%, 86%, 87%, and 80%, respectively) pattern (dissolution criterion Q=80% in 30 minutes) compared with the reference brand (88% dissolution in 30 minutes). The dissolution behavior was estimated with the reference brand using a model dependent and model-independent approach (f2>50, f1 < 15). A mechanistic mathematical release kinetics was also evaluated. The best-fit kinetic model was Hixon-Crowell release kinetics for reference brand and PRP1; and first order release kinetics was predominant for PRP2, PRP3 and PRP4.
Keywords: propranolol, dissolution, similarity factor, difference factor, dissolution kinetics
Keywords:
propranolol, dissolution, similarity factor, difference factor, dissolution kineticsDOI
https://doi.org/10.22270/jddt.v11i6-S.5225References
Zaborenko N, Shi Z, Corredor CC, Smith-Goettler BM, Zhang L, Hermans A, et al. First-Principles and Empirical Approaches to Predicting In Vitro Dissolution for Pharmaceutical Formulation and Process Development and for Product Release Testing. AAPS J. 2019; 21(3):21-32. https://doi.org/10.1208/s12248-019-0297-y
Eedara BB, Tucker IG, Das SC. In vitro dissolution testing of respirable size anti-tubercular drug particles using a small volume dissolution apparatus. Int J Pharm. 2019; 559:235-44. https://doi.org/10.1016/j.ijpharm.2019.01.035
Walsh EG, Adamczyk BE, Chalasani KB, Maher S, O'Toole EB, Fox JS, et al. Oral delivery of macromolecules: Rationale underpinning Gastrointestinal Permeation Enhancement Technology (GIPET®). Ther Deliv. 2011; 2(12):1595-610. https://doi.org/10.4155/tde.11.132
Smith AP, Moore TW, Westenberger BJ, Doub WH. In vitro dissolution of oral modified-release tablets and capsules in ethanolic media. Int J Pharm. 2010; 398(1-2):93-6. https://doi.org/10.1016/j.ijpharm.2010.07.031
Ilyés K, Balogh A, Casian T, Igricz T, Borbás E, Démuth B, et al. 3D floating tablets: Appropriate 3D design from the perspective of different in vitro dissolution testing methodologies. Int J Pharm. 2019; 567:118433. https://doi.org/10.1016/j.ijpharm.2019.06.024
Mehtani D, Seth A, Sharma P, Maheshwari R, Abed SN, Deb PK, et al. Dissolution Profile Consideration in Pharmaceutical Product Development. Dosage Form Design Considerations: Volume I. Elsevier Inc.; 2018; 287-336 p. https://doi.org/10.1016/B978-0-12-814423-7.00009-5
Molavi F, Hamishehkar H, Nokhodchi A. Impact of tablet shape on drug dissolution rate through immediate released tablets. Adv Pharm Bull. 2020; 10(4):656-61. https://doi.org/10.34172/apb.2020.079
Dey B, Katakam P, Assaleh FH, Chandu BR, Adiki SK, Mitra A. In vitro-in vivo studies of the quantitative effect of calcium, multivitamins and milk on single dose ciprofloxacin bioavailability. J Pharm Anal. 2015; 5(6):389-95. https://doi.org/10.1016/j.jpha.2015.02.003
Amidon GL, Lennernäs H, Shah VP, Crison JR. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability. Vol. 12, Pharmaceutical Research: An Official Journal of the American Association of Pharmaceutical Scientists. 1995. p. 413-20.
Lin Z, Zhou D, Hoag S, Qiu Y. Influence of Drug Properties and Formulation on In Vitro Drug Release and Biowaiver Regulation of Oral Extended Release Dosage Forms. AAPS J. 2016; 18(2):333-45. https://doi.org/10.1208/s12248-015-9861-2
Uppoor VRS. Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations. J Control Release. 2001; 72(1-3):127-32. https://doi.org/10.1016/S0168-3659(01)00268-1
De Spiegeleer B, Van Vooren L, Voorspoels J, Thoné D, Rosier J. Dissolution stability and IVIVC investigation of a buccal tablet. Anal Chim Acta. 2001; 446(1-2):343-9. https://doi.org/10.1016/S0003-2670(01)01074-1
Nguyen MA, Flanagan T, Brewster M, Kesisoglou F, Beato S, Biewenga J, et al. A survey on IVIVC/IVIVR development in the pharmaceutical industry - Past experience and current perspectives. Eur J Pharm Sci. 2017; 102:1-13. https://doi.org/10.1016/j.ejps.2017.02.029
Goodhart FW, McCoy RH, Ninger FC. New In Vitro Disintegration and Dissolution Test Method for Tablets and Capsules. J Pharm Sci. 1973 Feb 1; 62(2):304-10. https://doi.org/10.1002/jps.2600620227
Srinivasan A V. Propranolol: A 50-year historical perspective. Ann Indian Acad Neurol. 2019; 22(1):21-6. https://doi.org/10.4103/aian.AIAN_201_18
Liu X, Qu X, Zheng J, Zhang L. Effectiveness and safety of oral propranolol versus other treatments for infantile hemangiomas: A meta-analysis. PLoS One. 2015; 10(9):1-16. https://doi.org/10.1371/journal.pone.0138100
Menegola J, Steppe M, Schapoval EES. Dissolution test for citalopram in tablets and comparison of in vitro dissolution profiles. Eur J Pharm Biopharm. 2007; 67(2):524-30. https://doi.org/10.1016/j.ejpb.2007.02.009
Glass B. Counterfeit drugs and medical devices in developing countries. Res Rep Trop Med. 2014; 11. https://doi.org/10.2147/RRTM.S39354
Cook J, Addicks W, Wu YH. Application of the Biopharmaceutical Classification System in Clinical Drug Development-An Industrial View. AAPS J. 2008; 10(2):306-10. https://doi.org/10.1208/s12248-008-9036-5
Palinkas LA, Horwitz SM, Green CA, Wisdom JP, Duan N, Hoagwood K. Purposeful Sampling for Qualitative Data Collection and Analysis in Mixed Method Implementation Research. Adm Policy Ment Heal Ment Heal Serv Res. 2015; 42(5):533-44. https://doi.org/10.1007/s10488-013-0528-y
Pheatt CB. Evaluation of U. S. Pharmacopeia Sampling Plans for Dissolution. J Qual Technol. 1980;12(3):158-64. https://doi.org/10.1080/00224065.1980.11980955
Conceição AP, Sá RR, da Silva VC, Ferreira M da S, Cazedey ECL, Magalhães HIF, et al. A comparative study of propranolol release by in vitro dissolution profiles in pharmaceutical formulations. Dissolution Technol. 2018; 25(4):54-61. https://doi.org/10.14227/DT250418P54
Hydrochloride P. Propranolol Hydrochloride Tablets » Propranolol Hydrochloride Tablets contain not less than 90 . 0 percent and not more than 110 . 0 Propranolol Hydrochloride and Hydrochlorothiazide Extended-Release Capsules » Propranolol Hydrochloride and Hydrochlorothi. 2012; (c):2011-3.
Polli JE, Rekhi GS, Augsburger LL, Shah VP. Methods to Compare Dissolution Profiles and a Rationale for Wide Dissolution Specifications for Metoprolol Tartrate tablets†. J Pharm Sci. 1997 Jun 1; 86(6):690-700. https://doi.org/10.1021/js960473x
Anderson NH, Bauer M, Boussac N, Khan-Malek R, Munden P, Sardaro M. An evaluation of fit factors and dissolution efficiency for the comparison of in vitro dissolution profiles. J Pharm Biomed Anal. 1998; 17(4-5):811-22. https://doi.org/10.1016/S0731-7085(98)00011-9
Mircioiu C, Voicu V, Anuta V, Tudose A, Celia C, Paolino D, et al. Mathematical modeling of release kinetics from supramolecular drug delivery systems. Pharmaceutics. 2019; 11(3):1-45. https://doi.org/10.3390/pharmaceutics11030140
Mohapatra S, Kar RK, Sahoo SK. Goodness of fit model dependent approaches of controlled release matrix tablets of zidovudine. Indian J Pharm Educ Res. 2016; 50(1):138-45. https://doi.org/10.5530/ijper.50.1.18
Simionato LD, Petrone L, Baldut M, Bonafede SL, Segall AI. Comparison between the dissolution profiles of nine meloxicam tablet brands commercially available in Buenos Aires, Argentina. Saudi Pharm J [Internet]. 2018; 26(4):578-84. https://doi.org/10.1016/j.jsps.2018.01.015
Zhang Y, Huo M, Zhou J, Zou A, Li W, Yao C, et al. DDSolver: An add-in program for modeling and comparison of drug dissolution profiles. AAPS J. 2010; 12(3):263-71. https://doi.org/10.1208/s12248-010-9185-1
Umeta B, Bekele A, Mohammed T, Duguma M, Teshome H, Mekonnen Y. Dissolution profile evaluation of eight brands of metformin hydrochloride tablets available in Jimma, Southwest Ethiopia. Diabetes, Metab Syndr Obes Targets Ther. 2021; 14:3499-506. https://doi.org/10.2147/DMSO.S316187
Abraham W, Abuye H, Kebede S, Suleman S. In Vitro Comparative Quality Assessment of Different Brands of Doxycycline Hyclate Finished Dosage Forms: Capsule and Tablet in Jimma Town, South-West Ethiopia. Youssef TE, editor. Adv Pharmacol Pharm Sci. 2021; 2021:6645876. https://doi.org/10.1155/2021/6645876
Published
Abstract Display: 677 
PDF Downloads: 623 PDF Downloads: 165 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.